nodes	percent_of_prediction	percent_of_DWPC	metapath
Tretinoin—peripheral nervous system neoplasm—bone cancer	0.569	1	CtDrD
Tretinoin—CYP3A4—bone cancer	0.137	1	CbGaD
Tretinoin—CYP4A11—Cisplatin—bone cancer	0.0991	0.75	CbGbCtD
Tretinoin—CYP2B6—Cisplatin—bone cancer	0.0138	0.104	CbGbCtD
Tretinoin—CYP2B6—Doxorubicin—bone cancer	0.00922	0.0698	CbGbCtD
Tretinoin—CYP2C9—Cisplatin—bone cancer	0.00727	0.055	CbGbCtD
Tretinoin—CYP3A4—Doxorubicin—bone cancer	0.00283	0.0214	CbGbCtD
Tretinoin—ALDH1A1—Idarubicin—Epirubicin—bone cancer	0.00104	0.519	CbGdCrCtD
Tretinoin—ALDH1A1—Idarubicin—Doxorubicin—bone cancer	0.000966	0.481	CbGdCrCtD
Tretinoin—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	8.6e-05	0.00114	CbGpPWpGaD
Tretinoin—CYP2C18—FOXA1 transcription factor network—JUN—bone cancer	8.25e-05	0.00109	CbGpPWpGaD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	8.21e-05	0.00109	CbGpPWpGaD
Tretinoin—RARA—Adipogenesis—RB1—bone cancer	8.15e-05	0.00108	CbGpPWpGaD
Tretinoin—CYP2A6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	7.96e-05	0.00105	CbGpPWpGaD
Tretinoin—CYP4A11—Biological oxidations—CYP3A4—bone cancer	7.94e-05	0.00105	CbGpPWpGaD
Tretinoin—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	7.92e-05	0.00105	CbGpPWpGaD
Tretinoin—CYP2B6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	7.82e-05	0.00104	CbGpPWpGaD
Tretinoin—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	7.74e-05	0.00103	CbGpPWpGaD
Tretinoin—CYP4A11—NRF2 pathway—GSTP1—bone cancer	7.74e-05	0.00102	CbGpPWpGaD
Tretinoin—CYP4A11—NRF2 pathway—TGFBR2—bone cancer	7.74e-05	0.00102	CbGpPWpGaD
Tretinoin—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	7.73e-05	0.00102	CbGpPWpGaD
Tretinoin—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	7.64e-05	0.00101	CbGpPWpGaD
Tretinoin—RARG—Gene Expression—FUS—bone cancer	7.63e-05	0.00101	CbGpPWpGaD
Tretinoin—RXRA—Transcriptional regulation of white adipocyte differentiation—CDK4—bone cancer	7.42e-05	0.000983	CbGpPWpGaD
Tretinoin—RXRA—Regulation of Androgen receptor activity—MDM2—bone cancer	7.42e-05	0.000983	CbGpPWpGaD
Tretinoin—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	7.31e-05	0.000969	CbGpPWpGaD
Tretinoin—CYP1A1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	7.22e-05	0.000956	CbGpPWpGaD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	7.18e-05	0.000951	CbGpPWpGaD
Tretinoin—RXRA—Gene Expression—ZNF77—bone cancer	7e-05	0.000927	CbGpPWpGaD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	6.98e-05	0.000924	CbGpPWpGaD
Tretinoin—RXRG—Gene Expression—FUS—bone cancer	6.98e-05	0.000924	CbGpPWpGaD
Tretinoin—CYP2C18—Biological oxidations—CYP3A4—bone cancer	6.94e-05	0.000919	CbGpPWpGaD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	6.89e-05	0.000912	CbGpPWpGaD
Tretinoin—RARB—Gene Expression—FUS—bone cancer	6.84e-05	0.000906	CbGpPWpGaD
Tretinoin—CYP2C18—Metapathway biotransformation—CYP3A4—bone cancer	6.84e-05	0.000906	CbGpPWpGaD
Tretinoin—CYP4A11—Biological oxidations—GSTP1—bone cancer	6.79e-05	0.000899	CbGpPWpGaD
Tretinoin—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	6.71e-05	0.000888	CbGpPWpGaD
Tretinoin—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	6.62e-05	0.000876	CbGpPWpGaD
Tretinoin—RXRB—Gene Expression—FUS—bone cancer	6.56e-05	0.000869	CbGpPWpGaD
Tretinoin—RARA—Gene Expression—FUS—bone cancer	6.56e-05	0.000869	CbGpPWpGaD
Tretinoin—NR0B1—Gene Expression—NR1I2—bone cancer	6.56e-05	0.000869	CbGpPWpGaD
Tretinoin—RXRA—Regulation of Androgen receptor activity—JUN—bone cancer	6.45e-05	0.000854	CbGpPWpGaD
Tretinoin—CYP2B6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	6.42e-05	0.00085	CbGpPWpGaD
Tretinoin—Sweating—Epirubicin—bone cancer	6.39e-05	0.000755	CcSEcCtD
Tretinoin—Pollakiuria—Doxorubicin—bone cancer	6.39e-05	0.000755	CcSEcCtD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	6.36e-05	0.000842	CbGpPWpGaD
Tretinoin—Haematuria—Epirubicin—bone cancer	6.36e-05	0.000751	CcSEcCtD
Tretinoin—Pharyngitis—Methotrexate—bone cancer	6.35e-05	0.00075	CcSEcCtD
Tretinoin—Urinary tract disorder—Methotrexate—bone cancer	6.31e-05	0.000746	CcSEcCtD
Tretinoin—Photosensitivity reaction—Doxorubicin—bone cancer	6.31e-05	0.000746	CcSEcCtD
Tretinoin—Weight increased—Doxorubicin—bone cancer	6.3e-05	0.000744	CcSEcCtD
Tretinoin—RXRA—Biological oxidations—CYP3A4—bone cancer	6.3e-05	0.000834	CbGpPWpGaD
Tretinoin—Epistaxis—Epirubicin—bone cancer	6.29e-05	0.000743	CcSEcCtD
Tretinoin—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	6.28e-05	0.000831	CbGpPWpGaD
Tretinoin—Urethral disorder—Methotrexate—bone cancer	6.27e-05	0.000741	CcSEcCtD
Tretinoin—Weight decreased—Doxorubicin—bone cancer	6.26e-05	0.00074	CcSEcCtD
Tretinoin—Sinusitis—Epirubicin—bone cancer	6.25e-05	0.000739	CcSEcCtD
Tretinoin—Agranulocytosis—Epirubicin—bone cancer	6.22e-05	0.000735	CcSEcCtD
Tretinoin—Pneumonia—Doxorubicin—bone cancer	6.2e-05	0.000733	CcSEcCtD
Tretinoin—Infestation—Doxorubicin—bone cancer	6.17e-05	0.000729	CcSEcCtD
Tretinoin—Infestation NOS—Doxorubicin—bone cancer	6.17e-05	0.000729	CcSEcCtD
Tretinoin—Drowsiness—Doxorubicin—bone cancer	6.17e-05	0.000729	CcSEcCtD
Tretinoin—Visual impairment—Methotrexate—bone cancer	6.16e-05	0.000728	CcSEcCtD
Tretinoin—RXRA—NRF2 pathway—GSTP1—bone cancer	6.14e-05	0.000813	CbGpPWpGaD
Tretinoin—RXRA—NRF2 pathway—TGFBR2—bone cancer	6.14e-05	0.000813	CbGpPWpGaD
Tretinoin—Stevens-Johnson syndrome—Doxorubicin—bone cancer	6.11e-05	0.000723	CcSEcCtD
Tretinoin—Hypersensitivity—Cisplatin—bone cancer	6.1e-05	0.000721	CcSEcCtD
Tretinoin—Renal failure—Doxorubicin—bone cancer	6.06e-05	0.000717	CcSEcCtD
Tretinoin—Erythema multiforme—Methotrexate—bone cancer	6.05e-05	0.000715	CcSEcCtD
Tretinoin—Neuropathy peripheral—Doxorubicin—bone cancer	6.05e-05	0.000715	CcSEcCtD
Tretinoin—Haemoglobin—Epirubicin—bone cancer	6.01e-05	0.000711	CcSEcCtD
Tretinoin—Stomatitis—Doxorubicin—bone cancer	6.01e-05	0.000711	CcSEcCtD
Tretinoin—Urinary tract infection—Doxorubicin—bone cancer	6e-05	0.000709	CcSEcCtD
Tretinoin—Conjunctivitis—Doxorubicin—bone cancer	6e-05	0.000709	CcSEcCtD
Tretinoin—Hepatitis—Epirubicin—bone cancer	5.98e-05	0.000707	CcSEcCtD
Tretinoin—Haemorrhage—Epirubicin—bone cancer	5.98e-05	0.000707	CcSEcCtD
Tretinoin—Eye disorder—Methotrexate—bone cancer	5.98e-05	0.000706	CcSEcCtD
Tretinoin—Tinnitus—Methotrexate—bone cancer	5.96e-05	0.000705	CcSEcCtD
Tretinoin—Hypoaesthesia—Epirubicin—bone cancer	5.95e-05	0.000704	CcSEcCtD
Tretinoin—Asthenia—Cisplatin—bone cancer	5.94e-05	0.000702	CcSEcCtD
Tretinoin—Pharyngitis—Epirubicin—bone cancer	5.94e-05	0.000702	CcSEcCtD
Tretinoin—CYP2C18—Biological oxidations—GSTP1—bone cancer	5.93e-05	0.000786	CbGpPWpGaD
Tretinoin—CYP1A1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	5.93e-05	0.000785	CbGpPWpGaD
Tretinoin—Sweating—Doxorubicin—bone cancer	5.91e-05	0.000699	CcSEcCtD
Tretinoin—Urinary tract disorder—Epirubicin—bone cancer	5.91e-05	0.000698	CcSEcCtD
Tretinoin—Oedema peripheral—Epirubicin—bone cancer	5.89e-05	0.000697	CcSEcCtD
Tretinoin—Haematuria—Doxorubicin—bone cancer	5.88e-05	0.000695	CcSEcCtD
Tretinoin—Urethral disorder—Epirubicin—bone cancer	5.87e-05	0.000693	CcSEcCtD
Tretinoin—CYP2C18—Metapathway biotransformation—GSTP1—bone cancer	5.85e-05	0.000775	CbGpPWpGaD
Tretinoin—Epistaxis—Doxorubicin—bone cancer	5.82e-05	0.000688	CcSEcCtD
Tretinoin—Angiopathy—Methotrexate—bone cancer	5.8e-05	0.000686	CcSEcCtD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	5.79e-05	0.000767	CbGpPWpGaD
Tretinoin—Sinusitis—Doxorubicin—bone cancer	5.79e-05	0.000684	CcSEcCtD
Tretinoin—RXRA—a6b1 and a6b4 Integrin signaling—EGFR—bone cancer	5.78e-05	0.000765	CbGpPWpGaD
Tretinoin—Visual impairment—Epirubicin—bone cancer	5.77e-05	0.000682	CcSEcCtD
Tretinoin—Agranulocytosis—Doxorubicin—bone cancer	5.76e-05	0.00068	CcSEcCtD
Tretinoin—Chills—Methotrexate—bone cancer	5.74e-05	0.000678	CcSEcCtD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	5.71e-05	0.000756	CbGpPWpGaD
Tretinoin—Diarrhoea—Cisplatin—bone cancer	5.66e-05	0.000669	CcSEcCtD
Tretinoin—Erythema multiforme—Epirubicin—bone cancer	5.66e-05	0.000669	CcSEcCtD
Tretinoin—Alopecia—Methotrexate—bone cancer	5.65e-05	0.000668	CcSEcCtD
Tretinoin—Mental disorder—Methotrexate—bone cancer	5.6e-05	0.000662	CcSEcCtD
Tretinoin—Eye disorder—Epirubicin—bone cancer	5.59e-05	0.000661	CcSEcCtD
Tretinoin—Tinnitus—Epirubicin—bone cancer	5.58e-05	0.000659	CcSEcCtD
Tretinoin—Malnutrition—Methotrexate—bone cancer	5.57e-05	0.000658	CcSEcCtD
Tretinoin—Erythema—Methotrexate—bone cancer	5.57e-05	0.000658	CcSEcCtD
Tretinoin—Haemoglobin—Doxorubicin—bone cancer	5.57e-05	0.000658	CcSEcCtD
Tretinoin—Flushing—Epirubicin—bone cancer	5.55e-05	0.000656	CcSEcCtD
Tretinoin—Haemorrhage—Doxorubicin—bone cancer	5.54e-05	0.000654	CcSEcCtD
Tretinoin—Hepatitis—Doxorubicin—bone cancer	5.54e-05	0.000654	CcSEcCtD
Tretinoin—Hypoaesthesia—Doxorubicin—bone cancer	5.51e-05	0.000651	CcSEcCtD
Tretinoin—Pharyngitis—Doxorubicin—bone cancer	5.5e-05	0.000649	CcSEcCtD
Tretinoin—Urinary tract disorder—Doxorubicin—bone cancer	5.47e-05	0.000646	CcSEcCtD
Tretinoin—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	5.46e-05	0.000723	CbGpPWpGaD
Tretinoin—Oedema peripheral—Doxorubicin—bone cancer	5.45e-05	0.000645	CcSEcCtD
Tretinoin—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	5.44e-05	0.00072	CbGpPWpGaD
Tretinoin—Angiopathy—Epirubicin—bone cancer	5.43e-05	0.000642	CcSEcCtD
Tretinoin—Urethral disorder—Doxorubicin—bone cancer	5.43e-05	0.000641	CcSEcCtD
Tretinoin—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	5.39e-05	0.000713	CbGpPWpGaD
Tretinoin—Back pain—Methotrexate—bone cancer	5.38e-05	0.000636	CcSEcCtD
Tretinoin—RXRA—Biological oxidations—GSTP1—bone cancer	5.38e-05	0.000713	CbGpPWpGaD
Tretinoin—Chills—Epirubicin—bone cancer	5.37e-05	0.000635	CcSEcCtD
Tretinoin—Arrhythmia—Epirubicin—bone cancer	5.35e-05	0.000632	CcSEcCtD
Tretinoin—Visual impairment—Doxorubicin—bone cancer	5.34e-05	0.000631	CcSEcCtD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	5.33e-05	0.000705	CbGpPWpGaD
Tretinoin—RARG—Gene Expression—NR1I2—bone cancer	5.29e-05	0.0007	CbGpPWpGaD
Tretinoin—Alopecia—Epirubicin—bone cancer	5.29e-05	0.000625	CcSEcCtD
Tretinoin—Vomiting—Cisplatin—bone cancer	5.26e-05	0.000622	CcSEcCtD
Tretinoin—Vision blurred—Methotrexate—bone cancer	5.25e-05	0.00062	CcSEcCtD
Tretinoin—Mental disorder—Epirubicin—bone cancer	5.24e-05	0.00062	CcSEcCtD
Tretinoin—Erythema multiforme—Doxorubicin—bone cancer	5.24e-05	0.000619	CcSEcCtD
Tretinoin—Rash—Cisplatin—bone cancer	5.22e-05	0.000617	CcSEcCtD
Tretinoin—Dermatitis—Cisplatin—bone cancer	5.22e-05	0.000616	CcSEcCtD
Tretinoin—Erythema—Epirubicin—bone cancer	5.21e-05	0.000616	CcSEcCtD
Tretinoin—Malnutrition—Epirubicin—bone cancer	5.21e-05	0.000616	CcSEcCtD
Tretinoin—Eye disorder—Doxorubicin—bone cancer	5.17e-05	0.000612	CcSEcCtD
Tretinoin—Ill-defined disorder—Methotrexate—bone cancer	5.16e-05	0.00061	CcSEcCtD
Tretinoin—Tinnitus—Doxorubicin—bone cancer	5.16e-05	0.00061	CcSEcCtD
Tretinoin—Anaemia—Methotrexate—bone cancer	5.14e-05	0.000608	CcSEcCtD
Tretinoin—Flushing—Doxorubicin—bone cancer	5.14e-05	0.000607	CcSEcCtD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	5.13e-05	0.00068	CbGpPWpGaD
Tretinoin—Flatulence—Epirubicin—bone cancer	5.13e-05	0.000607	CcSEcCtD
Tretinoin—Tension—Epirubicin—bone cancer	5.11e-05	0.000604	CcSEcCtD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	5.11e-05	0.000676	CbGpPWpGaD
Tretinoin—Nervousness—Epirubicin—bone cancer	5.06e-05	0.000598	CcSEcCtD
Tretinoin—Back pain—Epirubicin—bone cancer	5.04e-05	0.000595	CcSEcCtD
Tretinoin—Angiopathy—Doxorubicin—bone cancer	5.02e-05	0.000594	CcSEcCtD
Tretinoin—Malaise—Methotrexate—bone cancer	5.02e-05	0.000593	CcSEcCtD
Tretinoin—Chills—Doxorubicin—bone cancer	4.97e-05	0.000587	CcSEcCtD
Tretinoin—Arrhythmia—Doxorubicin—bone cancer	4.95e-05	0.000585	CcSEcCtD
Tretinoin—RXRA—Generic Transcription Pathway—NR1I2—bone cancer	4.92e-05	0.000652	CbGpPWpGaD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	4.92e-05	0.000652	CbGpPWpGaD
Tretinoin—Nausea—Cisplatin—bone cancer	4.92e-05	0.000581	CcSEcCtD
Tretinoin—Vision blurred—Epirubicin—bone cancer	4.91e-05	0.00058	CcSEcCtD
Tretinoin—Alopecia—Doxorubicin—bone cancer	4.89e-05	0.000578	CcSEcCtD
Tretinoin—CYP1A1—Aryl Hydrocarbon Receptor—RB1—bone cancer	4.88e-05	0.000646	CbGpPWpGaD
Tretinoin—Cough—Methotrexate—bone cancer	4.86e-05	0.000574	CcSEcCtD
Tretinoin—Mental disorder—Doxorubicin—bone cancer	4.85e-05	0.000573	CcSEcCtD
Tretinoin—NR0B1—Gene Expression—EIF2S1—bone cancer	4.85e-05	0.000642	CbGpPWpGaD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	4.84e-05	0.000641	CbGpPWpGaD
Tretinoin—RXRG—Gene Expression—NR1I2—bone cancer	4.84e-05	0.00064	CbGpPWpGaD
Tretinoin—Ill-defined disorder—Epirubicin—bone cancer	4.83e-05	0.000571	CcSEcCtD
Tretinoin—RXRA—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.83e-05	0.000639	CbGpPWpGaD
Tretinoin—Convulsion—Methotrexate—bone cancer	4.82e-05	0.00057	CcSEcCtD
Tretinoin—Erythema—Doxorubicin—bone cancer	4.82e-05	0.00057	CcSEcCtD
Tretinoin—Malnutrition—Doxorubicin—bone cancer	4.82e-05	0.00057	CcSEcCtD
Tretinoin—Anaemia—Epirubicin—bone cancer	4.81e-05	0.000569	CcSEcCtD
Tretinoin—Agitation—Epirubicin—bone cancer	4.79e-05	0.000566	CcSEcCtD
Tretinoin—CYP4A11—Metabolism—NDUFA12—bone cancer	4.76e-05	0.00063	CbGpPWpGaD
Tretinoin—Flatulence—Doxorubicin—bone cancer	4.75e-05	0.000561	CcSEcCtD
Tretinoin—RARB—Gene Expression—NR1I2—bone cancer	4.74e-05	0.000628	CbGpPWpGaD
Tretinoin—Myalgia—Methotrexate—bone cancer	4.74e-05	0.00056	CcSEcCtD
Tretinoin—Chest pain—Methotrexate—bone cancer	4.74e-05	0.00056	CcSEcCtD
Tretinoin—Arthralgia—Methotrexate—bone cancer	4.74e-05	0.00056	CcSEcCtD
Tretinoin—Tension—Doxorubicin—bone cancer	4.73e-05	0.000559	CcSEcCtD
Tretinoin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	4.71e-05	0.000556	CcSEcCtD
Tretinoin—Malaise—Epirubicin—bone cancer	4.7e-05	0.000555	CcSEcCtD
Tretinoin—Discomfort—Methotrexate—bone cancer	4.68e-05	0.000553	CcSEcCtD
Tretinoin—Nervousness—Doxorubicin—bone cancer	4.68e-05	0.000553	CcSEcCtD
Tretinoin—Syncope—Epirubicin—bone cancer	4.67e-05	0.000552	CcSEcCtD
Tretinoin—Back pain—Doxorubicin—bone cancer	4.66e-05	0.000551	CcSEcCtD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	4.63e-05	0.000613	CbGpPWpGaD
Tretinoin—CYP3A7—Biological oxidations—CYP3A4—bone cancer	4.61e-05	0.000611	CbGpPWpGaD
Tretinoin—Palpitations—Epirubicin—bone cancer	4.6e-05	0.000544	CcSEcCtD
Tretinoin—Confusional state—Methotrexate—bone cancer	4.58e-05	0.000541	CcSEcCtD
Tretinoin—Loss of consciousness—Epirubicin—bone cancer	4.58e-05	0.000541	CcSEcCtD
Tretinoin—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	4.55e-05	0.000602	CbGpPWpGaD
Tretinoin—RXRB—Gene Expression—NR1I2—bone cancer	4.55e-05	0.000602	CbGpPWpGaD
Tretinoin—RARA—Gene Expression—NR1I2—bone cancer	4.55e-05	0.000602	CbGpPWpGaD
Tretinoin—Cough—Epirubicin—bone cancer	4.55e-05	0.000537	CcSEcCtD
Tretinoin—Anaphylactic shock—Methotrexate—bone cancer	4.54e-05	0.000537	CcSEcCtD
Tretinoin—Vision blurred—Doxorubicin—bone cancer	4.54e-05	0.000537	CcSEcCtD
Tretinoin—CRABP1—Metabolism—ENO2—bone cancer	4.52e-05	0.000599	CbGpPWpGaD
Tretinoin—CRABP2—Metabolism—ENO2—bone cancer	4.52e-05	0.000599	CbGpPWpGaD
Tretinoin—ALDH1A1—Metabolism—ENO2—bone cancer	4.52e-05	0.000599	CbGpPWpGaD
Tretinoin—Convulsion—Epirubicin—bone cancer	4.51e-05	0.000533	CcSEcCtD
Tretinoin—Infection—Methotrexate—bone cancer	4.51e-05	0.000533	CcSEcCtD
Tretinoin—Hypertension—Epirubicin—bone cancer	4.5e-05	0.000532	CcSEcCtD
Tretinoin—Ill-defined disorder—Doxorubicin—bone cancer	4.47e-05	0.000529	CcSEcCtD
Tretinoin—Nervous system disorder—Methotrexate—bone cancer	4.46e-05	0.000527	CcSEcCtD
Tretinoin—Anaemia—Doxorubicin—bone cancer	4.45e-05	0.000526	CcSEcCtD
Tretinoin—Thrombocytopenia—Methotrexate—bone cancer	4.45e-05	0.000526	CcSEcCtD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	4.44e-05	0.000588	CbGpPWpGaD
Tretinoin—Myalgia—Epirubicin—bone cancer	4.43e-05	0.000524	CcSEcCtD
Tretinoin—Chest pain—Epirubicin—bone cancer	4.43e-05	0.000524	CcSEcCtD
Tretinoin—Arthralgia—Epirubicin—bone cancer	4.43e-05	0.000524	CcSEcCtD
Tretinoin—Agitation—Doxorubicin—bone cancer	4.43e-05	0.000523	CcSEcCtD
Tretinoin—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	4.42e-05	0.000586	CbGpPWpGaD
Tretinoin—Anxiety—Epirubicin—bone cancer	4.42e-05	0.000522	CcSEcCtD
Tretinoin—Skin disorder—Methotrexate—bone cancer	4.41e-05	0.000521	CcSEcCtD
Tretinoin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	4.4e-05	0.000521	CcSEcCtD
Tretinoin—Hyperhidrosis—Methotrexate—bone cancer	4.39e-05	0.000519	CcSEcCtD
Tretinoin—Discomfort—Epirubicin—bone cancer	4.38e-05	0.000518	CcSEcCtD
Tretinoin—Malaise—Doxorubicin—bone cancer	4.35e-05	0.000514	CcSEcCtD
Tretinoin—Dry mouth—Epirubicin—bone cancer	4.34e-05	0.000513	CcSEcCtD
Tretinoin—Anorexia—Methotrexate—bone cancer	4.33e-05	0.000512	CcSEcCtD
Tretinoin—Syncope—Doxorubicin—bone cancer	4.32e-05	0.000511	CcSEcCtD
Tretinoin—Confusional state—Epirubicin—bone cancer	4.29e-05	0.000507	CcSEcCtD
Tretinoin—Palpitations—Doxorubicin—bone cancer	4.26e-05	0.000503	CcSEcCtD
Tretinoin—Anaphylactic shock—Epirubicin—bone cancer	4.25e-05	0.000502	CcSEcCtD
Tretinoin—Oedema—Epirubicin—bone cancer	4.25e-05	0.000502	CcSEcCtD
Tretinoin—RXRA—Adipogenesis—RB1—bone cancer	4.25e-05	0.000562	CbGpPWpGaD
Tretinoin—Hypotension—Methotrexate—bone cancer	4.25e-05	0.000502	CcSEcCtD
Tretinoin—Loss of consciousness—Doxorubicin—bone cancer	4.24e-05	0.000501	CcSEcCtD
Tretinoin—CYP2A6—Biological oxidations—CYP3A4—bone cancer	4.23e-05	0.00056	CbGpPWpGaD
Tretinoin—Infection—Epirubicin—bone cancer	4.22e-05	0.000499	CcSEcCtD
Tretinoin—NR0B1—Gene Expression—EZH2—bone cancer	4.21e-05	0.000557	CbGpPWpGaD
Tretinoin—Cough—Doxorubicin—bone cancer	4.21e-05	0.000497	CcSEcCtD
Tretinoin—ALDH1A1—Metabolism—DHFR—bone cancer	4.2e-05	0.000556	CbGpPWpGaD
Tretinoin—CRABP2—Metabolism—DHFR—bone cancer	4.2e-05	0.000556	CbGpPWpGaD
Tretinoin—CRABP1—Metabolism—DHFR—bone cancer	4.2e-05	0.000556	CbGpPWpGaD
Tretinoin—Shock—Epirubicin—bone cancer	4.18e-05	0.000494	CcSEcCtD
Tretinoin—CYP2A6—Fluoropyrimidine Activity—TP53—bone cancer	4.18e-05	0.000553	CbGpPWpGaD
Tretinoin—Convulsion—Doxorubicin—bone cancer	4.18e-05	0.000494	CcSEcCtD
Tretinoin—Nervous system disorder—Epirubicin—bone cancer	4.17e-05	0.000493	CcSEcCtD
Tretinoin—RXRA—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.17e-05	0.000552	CbGpPWpGaD
Tretinoin—Thrombocytopenia—Epirubicin—bone cancer	4.16e-05	0.000492	CcSEcCtD
Tretinoin—Hypertension—Doxorubicin—bone cancer	4.16e-05	0.000492	CcSEcCtD
Tretinoin—CYP2C18—Metabolism—NDUFA12—bone cancer	4.16e-05	0.000551	CbGpPWpGaD
Tretinoin—CYP1A1—Tryptophan metabolism—MDM2—bone cancer	4.16e-05	0.000551	CbGpPWpGaD
Tretinoin—Tachycardia—Epirubicin—bone cancer	4.15e-05	0.00049	CcSEcCtD
Tretinoin—Musculoskeletal discomfort—Methotrexate—bone cancer	4.14e-05	0.000489	CcSEcCtD
Tretinoin—Skin disorder—Epirubicin—bone cancer	4.13e-05	0.000488	CcSEcCtD
Tretinoin—CYP2A6—NRF2 pathway—GSTP1—bone cancer	4.12e-05	0.000546	CbGpPWpGaD
Tretinoin—CYP2A6—NRF2 pathway—TGFBR2—bone cancer	4.12e-05	0.000546	CbGpPWpGaD
Tretinoin—Hyperhidrosis—Epirubicin—bone cancer	4.11e-05	0.000486	CcSEcCtD
Tretinoin—Insomnia—Methotrexate—bone cancer	4.11e-05	0.000486	CcSEcCtD
Tretinoin—Myalgia—Doxorubicin—bone cancer	4.1e-05	0.000485	CcSEcCtD
Tretinoin—Chest pain—Doxorubicin—bone cancer	4.1e-05	0.000485	CcSEcCtD
Tretinoin—Arthralgia—Doxorubicin—bone cancer	4.1e-05	0.000485	CcSEcCtD
Tretinoin—Anxiety—Doxorubicin—bone cancer	4.09e-05	0.000483	CcSEcCtD
Tretinoin—Paraesthesia—Methotrexate—bone cancer	4.08e-05	0.000482	CcSEcCtD
Tretinoin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	4.08e-05	0.000482	CcSEcCtD
Tretinoin—Discomfort—Doxorubicin—bone cancer	4.05e-05	0.000479	CcSEcCtD
Tretinoin—Anorexia—Epirubicin—bone cancer	4.05e-05	0.000479	CcSEcCtD
Tretinoin—Dyspnoea—Methotrexate—bone cancer	4.05e-05	0.000479	CcSEcCtD
Tretinoin—Somnolence—Methotrexate—bone cancer	4.04e-05	0.000477	CcSEcCtD
Tretinoin—Dry mouth—Doxorubicin—bone cancer	4.01e-05	0.000474	CcSEcCtD
Tretinoin—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	4.01e-05	0.000531	CbGpPWpGaD
Tretinoin—Dyspepsia—Methotrexate—bone cancer	4e-05	0.000473	CcSEcCtD
Tretinoin—Hypotension—Epirubicin—bone cancer	3.97e-05	0.000469	CcSEcCtD
Tretinoin—Confusional state—Doxorubicin—bone cancer	3.97e-05	0.000469	CcSEcCtD
Tretinoin—Decreased appetite—Methotrexate—bone cancer	3.95e-05	0.000467	CcSEcCtD
Tretinoin—CYP3A7—Biological oxidations—GSTP1—bone cancer	3.94e-05	0.000522	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—NT5C3A—bone cancer	3.94e-05	0.000522	CbGpPWpGaD
Tretinoin—Anaphylactic shock—Doxorubicin—bone cancer	3.93e-05	0.000465	CcSEcCtD
Tretinoin—Oedema—Doxorubicin—bone cancer	3.93e-05	0.000465	CcSEcCtD
Tretinoin—ALDH1A1—Metabolism—GNA11—bone cancer	3.92e-05	0.000519	CbGpPWpGaD
Tretinoin—CRABP1—Metabolism—GNA11—bone cancer	3.92e-05	0.000519	CbGpPWpGaD
Tretinoin—CRABP2—Metabolism—GNA11—bone cancer	3.92e-05	0.000519	CbGpPWpGaD
Tretinoin—Gastrointestinal disorder—Methotrexate—bone cancer	3.92e-05	0.000464	CcSEcCtD
Tretinoin—Fatigue—Methotrexate—bone cancer	3.92e-05	0.000463	CcSEcCtD
Tretinoin—Infection—Doxorubicin—bone cancer	3.91e-05	0.000462	CcSEcCtD
Tretinoin—RARG—Gene Expression—EIF2S1—bone cancer	3.91e-05	0.000517	CbGpPWpGaD
Tretinoin—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	3.89e-05	0.000515	CbGpPWpGaD
Tretinoin—Pain—Methotrexate—bone cancer	3.88e-05	0.000459	CcSEcCtD
Tretinoin—Musculoskeletal discomfort—Epirubicin—bone cancer	3.87e-05	0.000458	CcSEcCtD
Tretinoin—Shock—Doxorubicin—bone cancer	3.87e-05	0.000457	CcSEcCtD
Tretinoin—Nervous system disorder—Doxorubicin—bone cancer	3.86e-05	0.000456	CcSEcCtD
Tretinoin—Thrombocytopenia—Doxorubicin—bone cancer	3.85e-05	0.000455	CcSEcCtD
Tretinoin—Insomnia—Epirubicin—bone cancer	3.85e-05	0.000454	CcSEcCtD
Tretinoin—Tachycardia—Doxorubicin—bone cancer	3.84e-05	0.000454	CcSEcCtD
Tretinoin—Skin disorder—Doxorubicin—bone cancer	3.82e-05	0.000452	CcSEcCtD
Tretinoin—Paraesthesia—Epirubicin—bone cancer	3.82e-05	0.000451	CcSEcCtD
Tretinoin—Hyperhidrosis—Doxorubicin—bone cancer	3.8e-05	0.000449	CcSEcCtD
Tretinoin—Dyspnoea—Epirubicin—bone cancer	3.79e-05	0.000448	CcSEcCtD
Tretinoin—Somnolence—Epirubicin—bone cancer	3.78e-05	0.000447	CcSEcCtD
Tretinoin—RXRA—Metabolism—NDUFA12—bone cancer	3.77e-05	0.0005	CbGpPWpGaD
Tretinoin—CYP1A1—Arachidonic acid metabolism—PTGS2—bone cancer	3.75e-05	0.000497	CbGpPWpGaD
Tretinoin—Anorexia—Doxorubicin—bone cancer	3.75e-05	0.000443	CcSEcCtD
Tretinoin—Feeling abnormal—Methotrexate—bone cancer	3.74e-05	0.000442	CcSEcCtD
Tretinoin—Dyspepsia—Epirubicin—bone cancer	3.74e-05	0.000442	CcSEcCtD
Tretinoin—Gastrointestinal pain—Methotrexate—bone cancer	3.71e-05	0.000439	CcSEcCtD
Tretinoin—Decreased appetite—Epirubicin—bone cancer	3.7e-05	0.000437	CcSEcCtD
Tretinoin—Hypotension—Doxorubicin—bone cancer	3.68e-05	0.000434	CcSEcCtD
Tretinoin—Gastrointestinal disorder—Epirubicin—bone cancer	3.67e-05	0.000434	CcSEcCtD
Tretinoin—Fatigue—Epirubicin—bone cancer	3.67e-05	0.000433	CcSEcCtD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.64e-05	0.000482	CbGpPWpGaD
Tretinoin—Pain—Epirubicin—bone cancer	3.64e-05	0.00043	CcSEcCtD
Tretinoin—Constipation—Epirubicin—bone cancer	3.64e-05	0.00043	CcSEcCtD
Tretinoin—CYP2A6—Biological oxidations—GSTP1—bone cancer	3.62e-05	0.000479	CbGpPWpGaD
Tretinoin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	3.61e-05	0.000479	CbGpPWpGaD
Tretinoin—Urticaria—Methotrexate—bone cancer	3.61e-05	0.000427	CcSEcCtD
Tretinoin—Abdominal pain—Methotrexate—bone cancer	3.59e-05	0.000424	CcSEcCtD
Tretinoin—Body temperature increased—Methotrexate—bone cancer	3.59e-05	0.000424	CcSEcCtD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	3.59e-05	0.000475	CbGpPWpGaD
Tretinoin—Musculoskeletal discomfort—Doxorubicin—bone cancer	3.58e-05	0.000424	CcSEcCtD
Tretinoin—RXRG—Gene Expression—EIF2S1—bone cancer	3.57e-05	0.000473	CbGpPWpGaD
Tretinoin—Insomnia—Doxorubicin—bone cancer	3.56e-05	0.00042	CcSEcCtD
Tretinoin—CRABP2—Metabolism—CYP3A4—bone cancer	3.56e-05	0.000471	CbGpPWpGaD
Tretinoin—CRABP1—Metabolism—CYP3A4—bone cancer	3.56e-05	0.000471	CbGpPWpGaD
Tretinoin—ALDH1A1—Metabolism—CYP3A4—bone cancer	3.56e-05	0.000471	CbGpPWpGaD
Tretinoin—CRABP1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.54e-05	0.000469	CbGpPWpGaD
Tretinoin—CRABP2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.54e-05	0.000469	CbGpPWpGaD
Tretinoin—Paraesthesia—Doxorubicin—bone cancer	3.53e-05	0.000417	CcSEcCtD
Tretinoin—Dyspnoea—Doxorubicin—bone cancer	3.51e-05	0.000414	CcSEcCtD
Tretinoin—Feeling abnormal—Epirubicin—bone cancer	3.5e-05	0.000414	CcSEcCtD
Tretinoin—RARB—Gene Expression—EIF2S1—bone cancer	3.5e-05	0.000464	CbGpPWpGaD
Tretinoin—Somnolence—Doxorubicin—bone cancer	3.5e-05	0.000413	CcSEcCtD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.49e-05	0.000462	CbGpPWpGaD
Tretinoin—Gastrointestinal pain—Epirubicin—bone cancer	3.48e-05	0.000411	CcSEcCtD
Tretinoin—Dyspepsia—Doxorubicin—bone cancer	3.46e-05	0.000409	CcSEcCtD
Tretinoin—CYP2C18—Metabolism—NT5C3A—bone cancer	3.45e-05	0.000456	CbGpPWpGaD
Tretinoin—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	3.44e-05	0.000455	CbGpPWpGaD
Tretinoin—Decreased appetite—Doxorubicin—bone cancer	3.42e-05	0.000404	CcSEcCtD
Tretinoin—RXRA—Gene Expression—FUS—bone cancer	3.42e-05	0.000453	CbGpPWpGaD
Tretinoin—CYP2B6—Biological oxidations—CYP3A4—bone cancer	3.41e-05	0.000452	CbGpPWpGaD
Tretinoin—Gastrointestinal disorder—Doxorubicin—bone cancer	3.4e-05	0.000401	CcSEcCtD
Tretinoin—RARG—Gene Expression—EZH2—bone cancer	3.39e-05	0.000449	CbGpPWpGaD
Tretinoin—Fatigue—Doxorubicin—bone cancer	3.39e-05	0.000401	CcSEcCtD
Tretinoin—Urticaria—Epirubicin—bone cancer	3.38e-05	0.000399	CcSEcCtD
Tretinoin—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	3.36e-05	0.000445	CbGpPWpGaD
Tretinoin—Pain—Doxorubicin—bone cancer	3.36e-05	0.000398	CcSEcCtD
Tretinoin—Constipation—Doxorubicin—bone cancer	3.36e-05	0.000398	CcSEcCtD
Tretinoin—Body temperature increased—Epirubicin—bone cancer	3.36e-05	0.000397	CcSEcCtD
Tretinoin—Abdominal pain—Epirubicin—bone cancer	3.36e-05	0.000397	CcSEcCtD
Tretinoin—RARA—Gene Expression—EIF2S1—bone cancer	3.36e-05	0.000445	CbGpPWpGaD
Tretinoin—RXRB—Gene Expression—EIF2S1—bone cancer	3.36e-05	0.000445	CbGpPWpGaD
Tretinoin—Hypersensitivity—Methotrexate—bone cancer	3.35e-05	0.000396	CcSEcCtD
Tretinoin—CYP3A5—Biological oxidations—CYP3A4—bone cancer	3.33e-05	0.000441	CbGpPWpGaD
Tretinoin—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	3.29e-05	0.000435	CbGpPWpGaD
Tretinoin—Asthenia—Methotrexate—bone cancer	3.26e-05	0.000385	CcSEcCtD
Tretinoin—Feeling abnormal—Doxorubicin—bone cancer	3.24e-05	0.000383	CcSEcCtD
Tretinoin—Gastrointestinal pain—Doxorubicin—bone cancer	3.22e-05	0.00038	CcSEcCtD
Tretinoin—Pruritus—Methotrexate—bone cancer	3.21e-05	0.00038	CcSEcCtD
Tretinoin—CYP1A1—Biological oxidations—CYP3A4—bone cancer	3.15e-05	0.000417	CbGpPWpGaD
Tretinoin—Hypersensitivity—Epirubicin—bone cancer	3.13e-05	0.00037	CcSEcCtD
Tretinoin—RXRA—Metabolism—NT5C3A—bone cancer	3.13e-05	0.000414	CbGpPWpGaD
Tretinoin—Urticaria—Doxorubicin—bone cancer	3.13e-05	0.000369	CcSEcCtD
Tretinoin—Abdominal pain—Doxorubicin—bone cancer	3.11e-05	0.000368	CcSEcCtD
Tretinoin—Body temperature increased—Doxorubicin—bone cancer	3.11e-05	0.000368	CcSEcCtD
Tretinoin—Diarrhoea—Methotrexate—bone cancer	3.11e-05	0.000367	CcSEcCtD
Tretinoin—CYP1A1—Metapathway biotransformation—CYP3A4—bone cancer	3.11e-05	0.000411	CbGpPWpGaD
Tretinoin—RXRG—Gene Expression—EZH2—bone cancer	3.1e-05	0.000411	CbGpPWpGaD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.06e-05	0.000405	CbGpPWpGaD
Tretinoin—Asthenia—Epirubicin—bone cancer	3.05e-05	0.00036	CcSEcCtD
Tretinoin—RARB—Gene Expression—EZH2—bone cancer	3.04e-05	0.000403	CbGpPWpGaD
Tretinoin—CRABP1—Metabolism—GSTP1—bone cancer	3.04e-05	0.000403	CbGpPWpGaD
Tretinoin—CRABP2—Metabolism—GSTP1—bone cancer	3.04e-05	0.000403	CbGpPWpGaD
Tretinoin—ALDH1A1—Metabolism—GSTP1—bone cancer	3.04e-05	0.000403	CbGpPWpGaD
Tretinoin—Pruritus—Epirubicin—bone cancer	3.01e-05	0.000355	CcSEcCtD
Tretinoin—Dizziness—Methotrexate—bone cancer	3e-05	0.000355	CcSEcCtD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.93e-05	0.000388	CbGpPWpGaD
Tretinoin—RXRB—Gene Expression—EZH2—bone cancer	2.92e-05	0.000386	CbGpPWpGaD
Tretinoin—RARA—Gene Expression—EZH2—bone cancer	2.92e-05	0.000386	CbGpPWpGaD
Tretinoin—CYP2B6—Biological oxidations—GSTP1—bone cancer	2.92e-05	0.000386	CbGpPWpGaD
Tretinoin—Diarrhoea—Epirubicin—bone cancer	2.91e-05	0.000344	CcSEcCtD
Tretinoin—Hypersensitivity—Doxorubicin—bone cancer	2.9e-05	0.000343	CcSEcCtD
Tretinoin—Vomiting—Methotrexate—bone cancer	2.89e-05	0.000341	CcSEcCtD
Tretinoin—CYP2C8—Biological oxidations—CYP3A4—bone cancer	2.89e-05	0.000382	CbGpPWpGaD
Tretinoin—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	2.88e-05	0.000381	CbGpPWpGaD
Tretinoin—Rash—Methotrexate—bone cancer	2.86e-05	0.000339	CcSEcCtD
Tretinoin—Dermatitis—Methotrexate—bone cancer	2.86e-05	0.000338	CcSEcCtD
Tretinoin—CYP3A5—Biological oxidations—GSTP1—bone cancer	2.85e-05	0.000378	CbGpPWpGaD
Tretinoin—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	2.85e-05	0.000377	CbGpPWpGaD
Tretinoin—Headache—Methotrexate—bone cancer	2.85e-05	0.000336	CcSEcCtD
Tretinoin—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	2.84e-05	0.000376	CbGpPWpGaD
Tretinoin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	2.84e-05	0.000376	CbGpPWpGaD
Tretinoin—Asthenia—Doxorubicin—bone cancer	2.82e-05	0.000334	CcSEcCtD
Tretinoin—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	2.81e-05	0.000372	CbGpPWpGaD
Tretinoin—Dizziness—Epirubicin—bone cancer	2.81e-05	0.000332	CcSEcCtD
Tretinoin—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	2.8e-05	0.00037	CbGpPWpGaD
Tretinoin—Pruritus—Doxorubicin—bone cancer	2.78e-05	0.000329	CcSEcCtD
Tretinoin—CYP3A7—Metabolism—NDUFA12—bone cancer	2.76e-05	0.000366	CbGpPWpGaD
Tretinoin—Vomiting—Epirubicin—bone cancer	2.7e-05	0.000319	CcSEcCtD
Tretinoin—Nausea—Methotrexate—bone cancer	2.7e-05	0.000319	CcSEcCtD
Tretinoin—CYP1A1—Biological oxidations—GSTP1—bone cancer	2.69e-05	0.000357	CbGpPWpGaD
Tretinoin—Diarrhoea—Doxorubicin—bone cancer	2.69e-05	0.000318	CcSEcCtD
Tretinoin—Rash—Epirubicin—bone cancer	2.68e-05	0.000317	CcSEcCtD
Tretinoin—Dermatitis—Epirubicin—bone cancer	2.68e-05	0.000317	CcSEcCtD
Tretinoin—Headache—Epirubicin—bone cancer	2.66e-05	0.000315	CcSEcCtD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.66e-05	0.000352	CbGpPWpGaD
Tretinoin—CYP1A1—Metapathway biotransformation—GSTP1—bone cancer	2.66e-05	0.000352	CbGpPWpGaD
Tretinoin—Dizziness—Doxorubicin—bone cancer	2.6e-05	0.000307	CcSEcCtD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.57e-05	0.00034	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—NDUFA12—bone cancer	2.53e-05	0.000336	CbGpPWpGaD
Tretinoin—Nausea—Epirubicin—bone cancer	2.53e-05	0.000298	CcSEcCtD
Tretinoin—Vomiting—Doxorubicin—bone cancer	2.5e-05	0.000296	CcSEcCtD
Tretinoin—Rash—Doxorubicin—bone cancer	2.48e-05	0.000293	CcSEcCtD
Tretinoin—Dermatitis—Doxorubicin—bone cancer	2.48e-05	0.000293	CcSEcCtD
Tretinoin—CYP2C8—Biological oxidations—GSTP1—bone cancer	2.47e-05	0.000327	CbGpPWpGaD
Tretinoin—Headache—Doxorubicin—bone cancer	2.46e-05	0.000291	CcSEcCtD
Tretinoin—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	2.44e-05	0.000323	CbGpPWpGaD
Tretinoin—RXRA—Gene Expression—NR1I2—bone cancer	2.37e-05	0.000314	CbGpPWpGaD
Tretinoin—CYP2C9—Biological oxidations—CYP3A4—bone cancer	2.35e-05	0.000311	CbGpPWpGaD
Tretinoin—Nausea—Doxorubicin—bone cancer	2.34e-05	0.000276	CcSEcCtD
Tretinoin—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	2.32e-05	0.000307	CbGpPWpGaD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.31e-05	0.000306	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—NT5C3A—bone cancer	2.29e-05	0.000303	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—NT5C3A—bone cancer	2.1e-05	0.000278	CbGpPWpGaD
Tretinoin—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	2.05e-05	0.000271	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—NDUFA12—bone cancer	2.04e-05	0.000271	CbGpPWpGaD
Tretinoin—CYP2C9—Biological oxidations—GSTP1—bone cancer	2.01e-05	0.000266	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—NDUFA12—bone cancer	2e-05	0.000265	CbGpPWpGaD
Tretinoin—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	1.98e-05	0.000263	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—NDUFA12—bone cancer	1.89e-05	0.00025	CbGpPWpGaD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.82e-05	0.000241	CbGpPWpGaD
Tretinoin—RXRA—Gene Expression—EIF2S1—bone cancer	1.75e-05	0.000232	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—NDUFA12—bone cancer	1.73e-05	0.000229	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—ENO2—bone cancer	1.73e-05	0.000229	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—NT5C3A—bone cancer	1.69e-05	0.000224	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—MET—bone cancer	1.68e-05	0.000222	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—CDK4—bone cancer	1.68e-05	0.000222	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—NT5C3A—bone cancer	1.66e-05	0.000219	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—DHFR—bone cancer	1.6e-05	0.000212	CbGpPWpGaD
Tretinoin—CRABP1—Metabolism—PTGS2—bone cancer	1.58e-05	0.000209	CbGpPWpGaD
Tretinoin—ALDH1A1—Metabolism—PTGS2—bone cancer	1.58e-05	0.000209	CbGpPWpGaD
Tretinoin—CRABP2—Metabolism—PTGS2—bone cancer	1.58e-05	0.000209	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—NT5C3A—bone cancer	1.56e-05	0.000207	CbGpPWpGaD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.53e-05	0.000202	CbGpPWpGaD
Tretinoin—RXRA—Gene Expression—EZH2—bone cancer	1.52e-05	0.000201	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—ENO2—bone cancer	1.51e-05	0.0002	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—GNA11—bone cancer	1.5e-05	0.000198	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—NT5C3A—bone cancer	1.43e-05	0.00019	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—NDUFA12—bone cancer	1.41e-05	0.000187	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—DHFR—bone cancer	1.4e-05	0.000185	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—MMP2—bone cancer	1.4e-05	0.000185	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—ENO2—bone cancer	1.37e-05	0.000181	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—CYP3A4—bone cancer	1.36e-05	0.00018	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.35e-05	0.000179	CbGpPWpGaD
Tretinoin—CYP3A4—Biological oxidations—GSTP1—bone cancer	1.33e-05	0.000176	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—GNA11—bone cancer	1.31e-05	0.000173	CbGpPWpGaD
Tretinoin—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	1.31e-05	0.000173	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—DHFR—bone cancer	1.27e-05	0.000168	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—GNA11—bone cancer	1.19e-05	0.000157	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—CYP3A4—bone cancer	1.19e-05	0.000157	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—NT5C3A—bone cancer	1.17e-05	0.000155	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—GSTP1—bone cancer	1.16e-05	0.000154	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—CYP3A4—bone cancer	1.08e-05	0.000143	CbGpPWpGaD
Tretinoin—RXRA—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.07e-05	0.000142	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—MMP9—bone cancer	1.05e-05	0.000139	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—GSTP1—bone cancer	1.01e-05	0.000134	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—ENO2—bone cancer	1e-05	0.000133	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—DHFR—bone cancer	9.31e-06	0.000123	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—NDUFA12—bone cancer	9.29e-06	0.000123	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—GSTP1—bone cancer	9.21e-06	0.000122	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—ENO2—bone cancer	9.2e-06	0.000122	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—GNA11—bone cancer	8.7e-06	0.000115	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—DHFR—bone cancer	8.53e-06	0.000113	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—EGFR—bone cancer	8.5e-06	0.000113	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—GNA11—bone cancer	7.97e-06	0.000106	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—CYP3A4—bone cancer	7.89e-06	0.000104	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—NT5C3A—bone cancer	7.7e-06	0.000102	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—ENO2—bone cancer	7.42e-06	9.83e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—ENO2—bone cancer	7.25e-06	9.6e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—CYP3A4—bone cancer	7.23e-06	9.57e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—DHFR—bone cancer	6.88e-06	9.12e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—ENO2—bone cancer	6.85e-06	9.07e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—GSTP1—bone cancer	6.75e-06	8.93e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—DHFR—bone cancer	6.73e-06	8.91e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—GNA11—bone cancer	6.43e-06	8.52e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—DHFR—bone cancer	6.36e-06	8.42e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—GNA11—bone cancer	6.29e-06	8.33e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—ENO2—bone cancer	6.28e-06	8.32e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—GSTP1—bone cancer	6.18e-06	8.19e-05	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—PTGS2—bone cancer	6.01e-06	7.96e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—GNA11—bone cancer	5.94e-06	7.87e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—CYP3A4—bone cancer	5.83e-06	7.72e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—DHFR—bone cancer	5.83e-06	7.72e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—CYP3A4—bone cancer	5.7e-06	7.55e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—GNA11—bone cancer	5.45e-06	7.21e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—CYP3A4—bone cancer	5.39e-06	7.13e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.36e-06	7.1e-05	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—PTGS2—bone cancer	5.26e-06	6.96e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—ENO2—bone cancer	5.11e-06	6.77e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—GSTP1—bone cancer	4.99e-06	6.61e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—CYP3A4—bone cancer	4.94e-06	6.54e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.91e-06	6.51e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—GSTP1—bone cancer	4.88e-06	6.46e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—PTGS2—bone cancer	4.77e-06	6.32e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—DHFR—bone cancer	4.74e-06	6.28e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—GSTP1—bone cancer	4.61e-06	6.1e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—GNA11—bone cancer	4.43e-06	5.87e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—GSTP1—bone cancer	4.22e-06	5.59e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—CYP3A4—bone cancer	4.02e-06	5.32e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4e-06	5.29e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—PTGS2—bone cancer	3.49e-06	4.63e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—GSTP1—bone cancer	3.44e-06	4.55e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—ENO2—bone cancer	3.37e-06	4.47e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—PTGS2—bone cancer	3.2e-06	4.24e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—DHFR—bone cancer	3.13e-06	4.14e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—GNA11—bone cancer	2.92e-06	3.87e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—PTGS2—bone cancer	2.58e-06	3.42e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—PTGS2—bone cancer	2.53e-06	3.35e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—PTGS2—bone cancer	2.39e-06	3.16e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—GSTP1—bone cancer	2.27e-06	3e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—PTGS2—bone cancer	2.19e-06	2.9e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—PTGS2—bone cancer	1.78e-06	2.36e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—PTGS2—bone cancer	1.17e-06	1.56e-05	CbGpPWpGaD
